RAPT Therapeutics (RAPT) EPS (Weighted Average and Diluted): 2021-2023
Historic EPS (Weighted Average and Diluted) for Therapeutics (RAPT) over the last 3 years, with Dec 2023 value amounting to -$0.81.
- Therapeutics' EPS (Weighted Average and Diluted) fell 24.62% to -$0.81 in Q4 2023 from the same period last year, while for Dec 2023 it was -$3.05, marking a year-over-year decrease of 17.76%. This contributed to the annual value of -$3.05 for FY2023, which is 18.22% down from last year.
- According to the latest figures from Q4 2023, Therapeutics' EPS (Weighted Average and Diluted) is -$0.81, which was up 1.22% from -$0.82 recorded in Q3 2023.
- Over the past 5 years, Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.61 during Q4 2021, and registered a low of -$0.82 during Q3 2023.
- For the 3-year period, Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.69, with its median value being -$0.66 (2023).
- As far as peak fluctuations go, Therapeutics' EPS (Weighted Average and Diluted) grew by 6.06% in 2022, and later crashed by 30.16% in 2023.
- Quarterly analysis of 3 years shows Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then decreased by 6.56% to -$0.65 in 2022, then declined by 24.62% to -$0.81 in 2023.
- Its EPS (Weighted Average and Diluted) was -$0.81 in Q4 2023, compared to -$0.82 in Q3 2023 and -$0.66 in Q2 2023.